Biogen Says Investors Can't Expand Alzheimer's Drug Suit

Biogen Inc. said a class of investors suing over alleged misleading statements in connection with the rollout of the company's Alzheimer's drug should not be allowed to needlessly delay resolution by...

Already a subscriber? Click here to view full article